Study of Anandron in Advanced Breast Cancer
Author Information
Author(s): M.J. Millward, B.M.J. Cantwell, M. Dowsett, J. Carmichael, A.L. Harris
Primary Institution: University Department of Clinical Oncology, Newcastle General Hospital
Hypothesis
Anandron may have therapeutic efficacy in post-menopausal women with advanced breast cancer without the virilizing side effects associated with androgens.
Conclusion
The study found no objective responses to Anandron, but two patients experienced disease stabilization for over 20 weeks.
Supporting Evidence
- Anandron was well tolerated in previous studies with men having prostate cancer.
- Two patients had disease stabilization for 26 and 20 weeks respectively.
- Previous studies indicated that a duration of disease stability can confer survival advantages.
Takeaway
Doctors tested a new medicine called Anandron on women with advanced breast cancer, but it didn't help most of them get better, although a couple of patients did stay stable for a while.
Methodology
Patients received 100 mg of Anandron daily and were assessed for response and toxicity over time.
Limitations
The study had a small sample size and lacked estrogen receptor measurements for most patients.
Participant Demographics
Post-menopausal women with advanced breast cancer, median age 70.
Statistical Information
P-Value
0.09
Statistical Significance
p=0.09
Want to read the original?
Access the complete publication on the publisher's website